BREXPIPRAZOLE - Generic Drug Details

What are the generic drug sources for brexpiprazole and what is the scope of freedom to operate?

Brexpiprazole is the generic ingredient in two branded drugs marketed by Ajanta Pharma Ltd, Alembic, Alkem Labs Ltd, Amneal, Apotex, Aurobindo Pharma Ltd, Chartwell Rx, Hetero Labs Ltd V, Lupin Ltd, Sandoz, Teva Pharms Usa Inc, Zydus Pharms, and Otsuka, and is included in thirteen NDAs. There are six patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Brexpiprazole has seventy-seven patent family members in thirty-nine countries.

There are eight drug master file entries for brexpiprazole. Three suppliers are listed for this compound. There are four tentative approvals for this compound.

Summary for BREXPIPRAZOLE

International Patents:	77
US Patents:	6
Tradenames:	2
Applicants:	13
NDAs:	13
Drug Master File Entries:	8
Finished Product Suppliers / Packagers:	3
Raw Ingredient (Bulk) Api Vendors:	78
Clinical Trials:	75
Patent Applications:	1,849
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for BREXPIPRAZOLE
What excipients (inactive ingredients) are in BREXPIPRAZOLE?	BREXPIPRAZOLE excipients list
DailyMed Link:	BREXPIPRAZOLE at DailyMed

Recent Clinical Trials for BREXPIPRAZOLE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Humanis Saglk Anonim Sirketi	PHASE1
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.	PHASE1
H. Lundbeck A/S	Phase 4

See all BREXPIPRAZOLE clinical trials

Generic filers with tentative approvals for BREXPIPRAZOLE

Applicant	Application No.	Strength	Dosage Form
		4MG	TABLET;ORAL
		3MG	TABLET;ORAL
		2MG	TABLET;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for BREXPIPRAZOLE

Drug Class

Atypical Antipsychotic

Anatomical Therapeutic Chemical (ATC) Classes for BREXPIPRAZOLE

N05AX	Other antipsychotics
N05A	ANTIPSYCHOTICS
N05	PSYCHOLEPTICS
N	Nervous system

Paragraph IV (Patent) Challenges for BREXPIPRAZOLE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
REXULTI	Tablets	brexpiprazole	4 mg	205422	16	2019-07-10

US Patents and Regulatory Information for BREXPIPRAZOLE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Lupin Ltd	BREXPIPRAZOLE	brexpiprazole	TABLET;ORAL	213512-003	Mar 17, 2023		DISCN	No	No
Hetero Labs Ltd V	BREXPIPRAZOLE	brexpiprazole	TABLET;ORAL	213669-003	Nov 20, 2023		DISCN	No	No
Teva Pharms Usa Inc	BREXPIPRAZOLE	brexpiprazole	TABLET;ORAL	213692-001	Aug 11, 2022		DISCN	No	No

EU/EMA Drug Approvals for BREXPIPRAZOLE

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Otsuka Pharmaceutical Netherlands B.V.	Rxulti	brexpiprazole	EMEA/H/C/003841Treatment of schizophrenia.	Authorised	no	no	no	2018-07-26

International Patents for BREXPIPRAZOLE

Country	Patent Number	Title	Estimated Expiration
Taiwan	I634908
Portugal	2767285
Cyprus	2018028

Supplementary Protection Certificates for BREXPIPRAZOLE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1869025	CA 2018 00028	Denmark		PRODUCT NAME: BREXPIPRAZOL ELLER ET SALT DERAF; REG. NO/DATE: EU/1/18/1294/001-006 20180727
1869025	2018/034	Ireland		PRODUCT NAME: BREXPIPRAZOLE OR A SALT THEREOF; NAT REGISTRATION NO/DATE: EU/1/18/1294 20180726; FIRST REGISTRATION NO/DATE: JOURNAL OF THE INTELLECTUAL PROPERTY OFFICE OF IRELAND (NO. 2402)
1869025	CR 2018 00028	Denmark		PRODUCT NAME: BREXPIPRAZOL ELLER ET SALT DERAF; REG. NO/DATE: EU/1/18/1294/001-006 20180727

Brexpiprazole: Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

Brexpiprazole, marketed as Rexulti by Otsuka Pharmaceutical and Lundbeck, is an atypical antipsychotic approved for the treatment of schizophrenia and as an adjunctive therapy for major depressive disorder (MDD). Its market performance is influenced by its therapeutic profile, patent exclusivity, and the competitive landscape of mental health treatments.

What is Brexpiprazole's Market Position?

Brexpiprazole is positioned as a second-generation antipsychotic with a unique mechanism of action, targeting dopamine D2 and serotonin 5-HT1A receptors as partial agonists, and serotonin 5-HT2A receptors as antagonists. This profile differentiates it from some older antipsychotics and allows for a nuanced therapeutic effect.

Key Market Indicators

• Approved Indications:
  • Schizophrenia in adults.
  • Adjunctive treatment for Major Depressive Disorder (MDD) in adults.
  • Treatment of agitation associated with dementia due to Alzheimer's disease (approved in select markets, such as Japan).
• Mechanism of Action: Partial agonism at D2 and 5-HT1A receptors, and antagonism at 5-HT2A receptors. This differs from aripiprazole, a related compound, which has a lower affinity for 5-HT1A partial agonism and higher affinity for D2 partial agonism.
• Competitive Landscape: Brexpiprazole competes with a range of antipsychotics and adjunctive treatments for MDD, including but not limited to:
  • Aripiprazole (Abilify)
  • Quetiapine (Seroquel)
  • Olanzapine (Zyprexa)
  • Cariprazine (Vraylar)
  • Brexpiprazole's primary competitor in the adjunctive MDD space includes established antidepressants like selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs), often used in combination with other augmentation agents.

What is Brexpiprazole's Patent and Exclusivity Status?

The patent landscape is critical to brexpiprazole's financial trajectory, determining the period of market exclusivity and the subsequent impact of generic competition.

Patent Expirations and Exclusivity Periods

• US Patents: Key patents for brexpiprazole and its formulations have expiration dates extending into the late 2020s and early 2030s. For instance, U.S. Patent No. 8,741,877, related to methods of treating schizophrenia and MDD, has an expiry in 2030, subject to potential patent term extensions [1].
• Global Filings: Otsuka and Lundbeck have secured patent protection in major pharmaceutical markets worldwide, including Europe and Japan.
• Data Exclusivity: In addition to patent protection, regulatory exclusivities (e.g., New Chemical Entity (NCE) exclusivity) provide market protection for a defined period after approval, regardless of patent status. This period is typically five years in the U.S. for NCEs [2].
• Upcoming Generic Entry: Analysts project that the first wave of generic brexpiprazole products will likely enter the U.S. market in the late 2020s, following the expiry of key patents and the resolution of any pending litigation. The timing of generic entry is subject to patent challenges and court decisions.

What are Brexpiprazole's Financial Performance and Market Size?

Brexpiprazole has demonstrated strong sales growth since its launch, driven by its efficacy in approved indications and expanding market penetration.

Sales Revenue and Growth

• 2022 Global Sales: Consolidated net sales for brexpiprazole (Rexulti) reached approximately $1.79 billion in 2022, a 14.5% increase from $1.56 billion in 2021 [3].
• Q4 2022 Performance: Net sales for the fourth quarter of 2022 were $481.7 million, up 10.1% compared to $437.3 million in the fourth quarter of 2021 [3].
• Projected Market Size: Market research reports forecast continued growth for brexpiprazole, with projected global sales exceeding $3 billion by the mid-2020s, before significant generic competition. This growth is attributed to its expanding use in schizophrenia and MDD, and potential new indications.
• Regional Breakdown: North America, particularly the United States, represents the largest market for brexpiprazole, followed by Europe and Japan.

Factors Influencing Financial Trajectory

• Market Penetration: Increasing adoption by psychiatrists and mental health professionals for both schizophrenia and adjunctive MDD treatment.
• Reimbursement: Favorable reimbursement policies from major payers are crucial for sustained sales growth.
• Clinical Data: Publication of positive clinical trial data supporting efficacy and safety across its approved indications reinforces physician confidence.
• Competition: The market remains competitive, with established and emerging treatments vying for market share.
• Post-Patent Exclusivity: The introduction of generic versions will lead to price erosion and a decline in brexpiprazole's market share and revenue. The speed and extent of this decline will depend on the number of generic entrants and their pricing strategies.

What is the Therapeutic Value and Clinical Significance of Brexpiprazole?

Brexpiprazole offers a distinct therapeutic profile, contributing to its clinical adoption.

Efficacy and Safety Profile

• Schizophrenia: Clinical trials have shown brexpiprazole to be effective in improving the positive and negative symptoms of schizophrenia. Its tolerability profile, including lower rates of weight gain and metabolic side effects compared to some older antipsychotics, is a significant advantage [4].
• Adjunctive MDD: In MDD, brexpiprazole has demonstrated efficacy in reducing depressive symptoms as an add-on therapy to standard antidepressant treatments. This addresses an unmet need for patients who do not achieve adequate remission with monotherapy [5].
• Side Effect Profile: Common side effects include akathisia (a feeling of inner restlessness), weight gain, somnolence, and headache. Its unique receptor binding profile is associated with a potentially different adverse event profile compared to other antipsychotics.
• Comparison to Aripiprazole: Brexpiprazole shares similarities with aripiprazole but exhibits a distinct receptor binding profile. This may translate to differences in efficacy for specific symptom domains and tolerability. Some studies suggest brexpiprazole may have a lower risk of akathisia compared to aripiprazole, although this is subject to ongoing clinical observation and meta-analysis [6].

Potential for New Indications

Ongoing research and clinical trials are exploring brexpiprazole's efficacy in other neurological and psychiatric conditions. Potential new indications could significantly expand its market and extend its commercial lifecycle.

What are the Future Market Outlook and Potential Challenges for Brexpiprazole?

The future of brexpiprazole will be shaped by the interplay of its established market position and the imminent threat of generic competition.

Key Considerations for the Future

• Genericization: The primary challenge for brexpiprazole post-patent expiry will be the influx of generic competitors. This typically leads to a significant price reduction and loss of market share for the originator product. The timeline for this is projected for the late 2020s.
• Lifecycle Management: Otsuka and Lundbeck will likely focus on strategies to mitigate the impact of genericization, such as developing new formulations (e.g., long-acting injectables) or exploring new therapeutic indications.
• Pricing and Reimbursement: As generics enter the market, pricing pressures will intensify. Reimbursement policies will continue to play a critical role in patient access and prescriber choice.
• Research and Development: Continued investment in R&D to identify and validate new uses for brexpiprazole could provide new revenue streams and extend its product lifecycle.
• Market Dynamics for Antipsychotics: The broader market for antipsychotics is characterized by ongoing innovation, with new agents and therapeutic approaches continuously emerging. Brexpiprazole must maintain its clinical value proposition against these advancements.

Key Takeaways

• Brexpiprazole (Rexulti) is a significant atypical antipsychotic with substantial global sales, projected to exceed $3 billion before generic entry.
• Its market exclusivity is primarily protected by patents expiring in the late 2020s and early 2030s, with generic competition anticipated to begin in the late 2020s.
• The drug's therapeutic value lies in its efficacy for schizophrenia and adjunctive treatment of MDD, with a distinct receptor binding profile influencing its tolerability.
• Future financial performance will be heavily influenced by the impact of genericization, lifecycle management strategies, and ongoing R&D for new indications.

Frequently Asked Questions

1. When is brexpiprazole projected to face significant generic competition? Significant generic competition for brexpiprazole is projected to commence in the United States in the late 2020s, contingent on patent expirations and the resolution of any ongoing legal challenges.

2. What are the primary approved indications for brexpiprazole? Brexpiprazole is approved for the treatment of schizophrenia in adults and as an adjunctive treatment for major depressive disorder (MDD) in adults. It is also approved in some regions for agitation associated with dementia due to Alzheimer's disease.

3. How does brexpiprazole's mechanism of action differ from aripiprazole? Brexpiprazole and aripiprazole both act as partial agonists at dopamine D2 and serotonin 5-HT1A receptors and antagonists at serotonin 5-HT2A receptors. However, brexpiprazole exhibits a lower intrinsic activity at the D2 receptor and a higher affinity for 5-HT1A partial agonism compared to aripiprazole, potentially leading to distinct clinical profiles.

4. What are the main revenue drivers for brexpiprazole currently? Current revenue for brexpiprazole is driven by its adoption in the treatment of schizophrenia and its role as an adjunctive therapy for MDD, with North America representing its largest market.

5. What strategies can pharmaceutical companies employ to mitigate the impact of generic competition for a drug like brexpiprazole? Companies can employ strategies such as developing new formulations (e.g., long-acting injectables), seeking approval for new therapeutic indications, or engaging in co-promotion agreements to extend product life and revenue streams beyond patent expiry.

Citations

[1] U.S. Patent No. 8,741,877. (2014). Methods of treating schizophrenia and major depressive disorder. United States Patent and Trademark Office. [2] Food and Drug Administration. (2019). FDA-Approved Drugs. Retrieved from https://www.fda.gov/drugs/development-approval-process/drug-development-process [3] Otsuka Holdings Co., Ltd. (2023). Consolidated Financial Results for Fiscal Year Ended December 31, 2022. [4] Correll, C. U., et al. (2016). Efficacy and safety of brexpiprazole for the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial. The American Journal of Psychiatry, 173(2), 231-240. [5] McIntyre, R. S., et al. (2016). Efficacy and safety of brexpiprazole as adjunctive treatment in patients with major depressive disorder: a randomized, double-blind, placebo-controlled study. Journal of Clinical Psychiatry, 77(8), 1018-1027. [6] Uchida, H., et al. (2017). Brexpiprazole versus aripiprazole in patients with schizophrenia: A meta-analysis of randomized controlled trials. Schizophrenia Research, 189, 300-305.